IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Safety and Feasibility Study of Dapivirine (TMC120) Vaginal Ring in Belgium
This study has been completed.
Sponsor:
International Partnership for Microbicides, Inc.
Collaborator:
Tibotec Pharmaceutical Limited
Information provided by:
International Partnership for Microbicides, Inc.
ClinicalTrials.gov Identifier:
NCT00332995
First received: June 1, 2006
Last updated: August 31, 2009
Last verified: August 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This Phase I trial will assess the feasibility of using a vaginal ring to deliver the candidate microbicide dapivirine (TMC120) for 7 days. The study population will consist of 13 healthy, sexually abstinent women. Safety and tolerability will be assessed through clinical and laboratory assessments. Feasibility of drug delivery will be assessed by measuring dapivirine (TMC120) concentrations in vaginal fluids, vaginal and cervical epithelial tissue, and plasma.
| Condition | Intervention | Phase |
|---|---|---|
| HIV Infections | Drug: dapivirine (TMC120) vaginal ring | Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Prevention |
| Official Title: | Double-blind, Randomized, Placebo Controlled Trial to Study Safety, Local and Systemic Availability of TMC120 From a Vaginal Ring. |
Resource links provided by NLM:
Further study details as provided by International Partnership for Microbicides, Inc.:
Primary Outcome Measures:
- Safety and tolerability of seven-day use of a vaginal ring containing dapivirine (TMC120).
- Assess dapivirine (TMC120) concentrations in vaginal fluids, vaginal and cervical epithelial tissue, and plasma during and after seven-day use of a vaginal ring containing dapivirine (TMC120).
| Estimated Enrollment: | 13 |
| Study Start Date: | July 2005 |
| Estimated Study Completion Date: | August 2005 |
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Female, age 18-50 years
- Willing and able to provide written informed consent
- HIV-uninfected and otherwise healthy
- Willing to abstain from sexual activity and from use of vaginal products while participating in the study
- Currently using oral contraceptives for pregnancy prevention
- Willing to use oral contraceptives as needed to avoid menstruation while taking part in this study
Exclusion Criteria:
- History of allergy to TMC120 or to the constituents of the vaginal ring
- History of diagnosis of and/or treatment for a sexually transmitted disease within the last three months
- History of genital tract surgery within the last month
- Currently pregnant or breastfeeding, or within two months of last pregnancy outcome
- Currently or within one month of participating in any other clinical research study
- Current vulvar or vaginal symptoms / abnormalities that could influence the study results
- Current non-iatrogenic pelvic/colposcopic exam findings involving deep epithelial disruption
- Current diagnosis of any genital infection
- Smoking more than 10 cigarettes / day
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00332995
Please refer to this study by its ClinicalTrials.gov identifier: NCT00332995
Locations
| Belgium | |
| Drug Research Unit Gent | |
| Gent, Belgium, 9000 | |
Sponsors and Collaborators
International Partnership for Microbicides, Inc.
Tibotec Pharmaceutical Limited
Investigators
| Principal Investigator: | Dr. Luc Van Bortel | University of Ghent |
More Information
| Responsible Party: | Zeda Rosenberg ScD, International Partnership for Microbicides |
| ClinicalTrials.gov Identifier: | NCT00332995 History of Changes |
| Other Study ID Numbers: |
IPM008, TMC120-C131 |
| Study First Received: | June 1, 2006 |
| Last Updated: | August 31, 2009 |
Keywords provided by International Partnership for Microbicides, Inc.:
|
HIV Seronegativity |
Additional relevant MeSH terms:
|
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases |
ClinicalTrials.gov processed this record on July 21, 2017